Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, pharmacokinetics, and efficacy of mosunetuzumab or glofitamab in combination with CC-220 and/or CC-99282 in participants with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CC-220
• CC-99282
• Glofitamab (glofitamab)
• Mosunetuzumab (mosunetuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING